Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

News Conference News EuroPCR 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Michael O'Riordan

May 29, 2025

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

News Conference News ESC 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

September 02, 2024

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

TCTMD’s Top 10 Most Popular Stories for November 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2019

November 29, 2019

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

September 20, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

TAVR Bleeds Stand Apart From PCI-Related Events

News Daily News

TAVR Bleeds Stand Apart From PCI-Related Events

August 06, 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

News Conference News ESC 2018

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

August 26, 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

TCTMD’s Top 10 Most Popular Stories for October 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

October 29, 2017

TCTMD’s Top 10 Most Popular Stories for September 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

September 30, 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.